GB1211 (Selvigaltin) Combination Therapy
Phase I Trial of GB1211 (Selvigaltin), an Oral Galectin-3 (Gal-3) Inhibitor, Combined With Standard of Care Treatment in Relapsed/Refractory Multiple Myeloma (RRMM)
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 21 patients (estimated)
- Sponsors
- Roswell Park Cancer Institute
- Trial Type
- Treatment
- Last Update
- 3 days ago
- SparkCures ID
- 2147
- NCT Identifier
- NCT07082270
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.